Ekso Bionics Reports Q1 2025 Financial Results

Ekso Bionics Holding ( (EKSO) ) has released its Q1 earnings. Here is a breakdown of the information Ekso Bionics Holding presented to its investors.

Ekso Bionics Holdings, Inc., a leader in exoskeleton technology for medical and industrial applications, has released its financial results for the first quarter of 2025, highlighting strategic partnerships and financial performance. The company reported a revenue of $3.4 million for the quarter, a decrease from $3.8 million in the same period last year, primarily due to lower sales of legacy devices. However, the company saw a positive impact from increased sales of its Ekso Indego® Personal device, supported by new distribution partnerships with National Seating & Mobility and Bionic Prosthetics & Orthotics Group. These partnerships are expected to enhance the company’s presence in the U.S. complex rehabilitation technology and orthotics and prosthetics industries. Ekso Bionics also improved its operating cash burn by 43% and raised $3.8 million from warrant exercises, strengthening its financial position. Despite a net loss of $2.9 million, the company reduced its net cash used in operations to $2.0 million, down from $3.5 million in the previous year. Looking ahead, Ekso Bionics is optimistic about the potential growth in its Personal Health products segment, driven by its recent strategic partnerships and ongoing efforts to enhance its product offerings.